Douglas A. Lauffenburger is Ford Professor of Bioengineering and (founding) Head of the Department of Biological Engineering at MIT.  Professor Lauffenburger also holds appointments in the Department of Biology and the Department of Chemical Engineering, is a member of the Center for Biomedical Engineering, Center for Environmental Health Sciences, Center for Gynepathology Research, and Koch Institute for Integrative Cancer Research.  A central focus of his research program is in receptor-mediated cell communication and intracellular signal transduction important in pathophysiology with application to drug discovery and development, with emphasis on development of predictive computational models derived from quantitative experimental studies.  More than 100 doctoral students and postdoctoral associates have undertaken research education under his supervision, and he has served as a consultant or scientific advisory board member for a number of bio/pharma companies including Applied BioMath, Array BioPharm, Astra-Zeneca, Complete Genomics, Entelos, Genentech, Immuneering, Merrimack Pharmaceuticals, Nodality, Pfizer, and Torque Therapeutics.